realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Criteria: Inclusion Criteria:

1. Age ≥18 years at the time of diagnosis of R/R DLBCL

2. Initiated or initiating tafasitamab treatment

3. R/R DLBCL patients who have received at least one (1) prior line of treatment forDLBCL

4. Histologically confirmed DLBCL such as: a) DLBCL not otherwise specified (NOS) b) T-cell histiocyte-rich large B-celllymphoma (THRLBCL) c) Epstein-Barr virus (EBV)-positive DLBCL of the elderly d)Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse, accordingto Revised European American Lymphoma (REAL)/World Health Organization (WHO)classification e) Patients with evidence of histological transformation to DLBCLfrom an earlier diagnosis of low-grade lymphoma (i.e., an indolent pathology such asfollicular lymphoma [FL], marginal zone lymphoma [MZL], chronic lymphocytic leukemia [CLL]) with a subsequent DLBCL relapse f) High-grade B-cell lymphoma: i) DLBCL withMYC and BCL2 or BCL6 translocation (double-hit) and MYC and BCL2 and BCL6translocations (triple-hit) ii) High-grade B-cell lymphoma, NOS

5. Signed and dated ICF by the patient or the patient's Legally AcceptableRepresentative (LAR), for patients with prospective data collection, as applicable.For deceased or otherwise unreachable patients, no informed consent will be obtainedfor data collection in the study, provided that the competent Independent EthicsCommittee (IEC)/Institutional Review Board (IRB) has provided favorable opinion andthat any other local regulatory requirements on this matter are met

Exclusion Criteria:

• Initiated or initiating tafasitamab treatment in the context of an interventional study.